Dimitry Nuyten
Chief Tech/Sci/R&D Officer bij ARCUS BIOSCIENCES, INC.
Vermogen: 2 M $ op 31-03-2024
Profiel
Dimitry S.
A.
Nuyten is currently the Chief Medical Officer at Arcus Biosciences, Inc. He previously worked as the Group Medical Director at Bristol Myers Squibb Co. from 2008 to 2013, and as the Vice President at Pfizer Inc. from 2013 to 2019.
In 2021, he was the Chief Medical Officer & Senior Vice President at Nektar Therapeutics.
He also served as the Chief Medical Officer at Aduro BioTech, Inc. Dr. Nuyten holds a doctorate degree from both the University of Amsterdam and the University of Groningen.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
ARCUS BIOSCIENCES, INC.
0.11% | 23-01-2024 | 99 195 ( 0.11% ) | 2 M $ | 31-03-2024 |
Actieve functies van Dimitry Nuyten
| Bedrijven | Functie | Begin |
|---|---|---|
| ARCUS BIOSCIENCES, INC. | Chief Tech/Sci/R&D Officer | 01-08-2022 |
Eerdere bekende functies van Dimitry Nuyten
| Bedrijven | Functie | Einde |
|---|---|---|
| NEKTAR THERAPEUTICS | Chief Tech/Sci/R&D Officer | 01-04-2022 |
| PFIZER, INC. | Corporate Officer/Principal | 01-03-2019 |
| BRISTOL-MYERS SQUIBB COMPANY | Chief Tech/Sci/R&D Officer | 01-06-2013 |
| CHINOOK THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | - |
Opleiding van Dimitry Nuyten
| University of Amsterdam | Doctorate Degree |
| University of Groningen | Doctorate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 4 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| PFIZER, INC. | Health Technology |
| NEKTAR THERAPEUTICS | Health Technology |
| ARCUS BIOSCIENCES, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Aduro BioTech, Inc.
 Aduro BioTech, Inc. Pharmaceuticals: MajorHealth Technology Aduro BioTech, Inc. is a clinical-stage immunotherapy company, which engages in the discovery, development, and commercialization of therapies that transform the treatment of diseases, including cancer. Its technology platforms include STING Pathway Activator, B-select monoclonal antibody, and LADD, or Live, Attenuated, Double-Deleted Listeria monocytogenes. The company's platforms stimulate and/or regulate innate and adaptive immune responses, either as single agents or in combination with conventional therapies like chemotherapy and radiation as well as other novel immunotherapies. Aduro BioTech was founded in 2000 and is headquartered in Berkeley, CA. | Health Technology |
